Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer

被引：0
作者：
Struss, Werner J. [1 ]
Black, Peter C. [1 ]
机构：
[1] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC, Canada
来源：
UROLOGY | 2017年 / 109卷
关键词：
THERAPY;
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1 / 2
页数：2
相关论文
共 50 条
  • [1] Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
    Messina, Carlo
    Messina, Marco
    Boccardo, Francesco
    EUROPEAN UROLOGY, 2018, 73 (01) : 147 - 148
  • [2] Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
    Chi, Kim N.
    Agarwal, Neeraj
    Bjartell, Anders
    Chung, Byung Ha
    Pereira de Santana Gomes, Andrea J.
    Given, Robert
    Juarez Soto, Alvaro
    Merseburger, Axel S.
    Ozguroglu, Mustafa
    Uemura, Hirotsugu
    Ye, Dingwei
    Deprince, Kris
    Naini, Vahid
    Li, Jinhui
    Cheng, Shinta
    Yu, Margaret K.
    Zhang, Ke
    Larsen, Julie S.
    McCarthy, Sharon
    Chowdhury, Simon
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (01) : 13 - 24
  • [3] The evolving options in metastatic castration-sensitive prostate cancer
    Hamilou, Zineb
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2020, 14 (03) : 270 - 275
  • [4] A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer
    Kwon, Daniel Hyuck-Min
    Friedlander, Terence
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [5] Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer
    Miyake, Hideaki
    Matsushita, Yuto
    Watanabe, Hiromitsu
    Tamura, Keita
    Motoyama, Daisuke
    Ito, Toshiki
    Sugiyama, Takayuki
    Otsuka, Atsushi
    ANTICANCER RESEARCH, 2019, 39 (03) : 1391 - 1396
  • [6] Balancing efficacy and financial toxicity in the management of metastatic castration-sensitive prostate cancer
    Sridhar, Srikala S.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2019, 13 (12): : 404 - 405
  • [7] Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer
    Sutera, P. A.
    Shetty, A. C.
    Hakansson, A.
    Van der Eecken, K.
    Song, Y.
    Liu, Y.
    Chang, J.
    Fonteyne, V.
    Mendes, A. A.
    Lumen, N.
    Delrue, L.
    Verbeke, S.
    De Man, K.
    Rana, Z.
    Hodges, T.
    Hamid, A.
    Roberts, N.
    Song, D. Y.
    Pienta, K.
    Ross, A. E.
    Feng, F.
    Joniau, S.
    Spratt, D.
    Gillessen, S.
    Attard, G.
    James, N. D.
    Lotan, T.
    Davicioni, E.
    Sweeney, C.
    Tran, P. T.
    Deek, M. P.
    Ost, P.
    ANNALS OF ONCOLOGY, 2023, 34 (07) : 605 - 614
  • [8] Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer
    Yang, Yun-Jie
    Kong, Yun-Yi
    Li, Gao-Xiang
    Wang, Yue
    Ye, Ding-Wei
    Dai, Bo
    BJU INTERNATIONAL, 2019, 124 (02) : 258 - 267
  • [9] Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study
    Lowentritt, Benjamin
    Pilon, Dominic
    Waters, Dexter
    Rossi, Carmine
    Muser, Erik
    Kurteva, Siyana
    Shah, Aditi
    Khilfeh, Ibrahim
    Du, Shawn
    Ellis, Lorie
    Lefebvre, Patrick
    Brown, Gordon
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (05) : 252.e19 - 252.e27
  • [10] Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer
    Briones, Juan
    Khan, Maira
    Sidhu, Amanjot K.
    Zhang, Liying
    Smoragiewicz, Martin
    Emmenegger, Urban
    FRONTIERS IN ONCOLOGY, 2021, 11
12345